Medifast (MED) Tops Q1 EPS by 3c, Offers Guidance

Medifast (NYSE: MED) reported Q1 EPS of $3.59, $0.03 better than the analyst estimate of $3.56. Revenue for the quarter came in at $417.6 million versus the consensus estimate of $402.42 million.

GUIDANCE:

Medifast sees FY2022 EPS of $14.60-$16.05, versus the consensus of $15.62. Medifast sees FY2022 revenue of $1.78-1.84 billion, versus the consensus of $1.77 billion.

For earnings history and earnings-related data on Medifast (MED) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Jiayin Group (JFIN) Reports Q2 Loss of RMB3.56
• SentinelOne, Inc. (S) Tops Q2 EPS by 1c; offers guidance